A M Api, A Bartlett, D Belsito, D Botelho, M Bruze, A Bryant-Friedrich, G A Burton, M A Cancellieri, H Chon, M Cronin, S Crotty, M L Dagli, W Dekant, C Deodhar, K Farrell, A D Fryer, L Jones, K Joshi, A Lapczynski, D L Laskin, M Lavelle, I Lee, H Moustakas, J Muldoon, T M Penning, A H Piersma, G Ritacco, N Sadekar, I Schember, T W Schultz, F Siddiqi, I G Sipes, G Sullivan, Y Thakkar
{"title":"天然复合物质(NCS)香料成分安全性评价,安息香注射液,苏门答腊,CAS注册号9000-05-9,RIFM ID 104-K2.31。","authors":"A M Api, A Bartlett, D Belsito, D Botelho, M Bruze, A Bryant-Friedrich, G A Burton, M A Cancellieri, H Chon, M Cronin, S Crotty, M L Dagli, W Dekant, C Deodhar, K Farrell, A D Fryer, L Jones, K Joshi, A Lapczynski, D L Laskin, M Lavelle, I Lee, H Moustakas, J Muldoon, T M Penning, A H Piersma, G Ritacco, N Sadekar, I Schember, T W Schultz, F Siddiqi, I G Sipes, G Sullivan, Y Thakkar","doi":"10.1016/j.fct.2025.115774","DOIUrl":null,"url":null,"abstract":"<p><p>Benzoin infusion, Sumatra was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, photoirritation/photoallergenicity, skin sensitization, and environmental safety. Data for the components of the NCS do not show a concern for genotoxicity. Benzoin infusion, Sumatra was evaluated for the repeated dose and reproductive toxicity endpoints on the basis of component analysis using a combination of target data, read-across data, and the threshold of toxicological concern (TTC); benzoin infusion, Sumatra is safe for use under the conditions described in this safety assessment for the repeated dose and reproductive toxicity endpoints. Data for the components of the NCS do not show a concern for skin sensitization under the current, declared levels of use. The photoirritation endpoint was evaluated based on data and ultraviolet/visible (UV/Vis) absorption spectra for the components of the NCS; benzoin infusion, Sumatra is not expected to be photoirritating. Benzoin infusion, Sumatra has not been fully evaluated for photoallergenicity due to a lack of suitable data and validated in vitro tests. To address this data gap, RIFM is sponsoring an in vitro photoallergy research program to evaluate the photoallergy potential of benzoin infusion, Sumatra. The local respiratory toxicity endpoint for this NCS was evaluated using the inhalation TTC for a Cramer Class III material, and the inhalation exposure to benzoin infusion, Sumatra is below the TTC (0.47 mg/day). Based on the component assessment, benzoin infusion, Sumatra does not contain Persistent, Bioaccumulative, and Toxic (PBT) or very Persistent, very Bioaccumulative (vPvB) components as per the IFRA Environmental Standards. In addition, following the RIFM Environmental Framework and based on individual component assessment, benzoin infusion, Sumatra does not present a risk to the aquatic environment (i.e., its screening-level PEC/PNEC <1) at the current reported VoU.</p>","PeriodicalId":317,"journal":{"name":"Food and Chemical Toxicology","volume":" ","pages":"115774"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RIFM Natural Complex Substance (NCS) fragrance ingredient safety assessment, benzoin infusion, Sumatra, CAS Registry Number 9000-05-9, RIFM ID 104-K2.31.\",\"authors\":\"A M Api, A Bartlett, D Belsito, D Botelho, M Bruze, A Bryant-Friedrich, G A Burton, M A Cancellieri, H Chon, M Cronin, S Crotty, M L Dagli, W Dekant, C Deodhar, K Farrell, A D Fryer, L Jones, K Joshi, A Lapczynski, D L Laskin, M Lavelle, I Lee, H Moustakas, J Muldoon, T M Penning, A H Piersma, G Ritacco, N Sadekar, I Schember, T W Schultz, F Siddiqi, I G Sipes, G Sullivan, Y Thakkar\",\"doi\":\"10.1016/j.fct.2025.115774\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Benzoin infusion, Sumatra was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, photoirritation/photoallergenicity, skin sensitization, and environmental safety. Data for the components of the NCS do not show a concern for genotoxicity. Benzoin infusion, Sumatra was evaluated for the repeated dose and reproductive toxicity endpoints on the basis of component analysis using a combination of target data, read-across data, and the threshold of toxicological concern (TTC); benzoin infusion, Sumatra is safe for use under the conditions described in this safety assessment for the repeated dose and reproductive toxicity endpoints. Data for the components of the NCS do not show a concern for skin sensitization under the current, declared levels of use. The photoirritation endpoint was evaluated based on data and ultraviolet/visible (UV/Vis) absorption spectra for the components of the NCS; benzoin infusion, Sumatra is not expected to be photoirritating. Benzoin infusion, Sumatra has not been fully evaluated for photoallergenicity due to a lack of suitable data and validated in vitro tests. To address this data gap, RIFM is sponsoring an in vitro photoallergy research program to evaluate the photoallergy potential of benzoin infusion, Sumatra. The local respiratory toxicity endpoint for this NCS was evaluated using the inhalation TTC for a Cramer Class III material, and the inhalation exposure to benzoin infusion, Sumatra is below the TTC (0.47 mg/day). Based on the component assessment, benzoin infusion, Sumatra does not contain Persistent, Bioaccumulative, and Toxic (PBT) or very Persistent, very Bioaccumulative (vPvB) components as per the IFRA Environmental Standards. In addition, following the RIFM Environmental Framework and based on individual component assessment, benzoin infusion, Sumatra does not present a risk to the aquatic environment (i.e., its screening-level PEC/PNEC <1) at the current reported VoU.</p>\",\"PeriodicalId\":317,\"journal\":{\"name\":\"Food and Chemical Toxicology\",\"volume\":\" \",\"pages\":\"115774\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Food and Chemical Toxicology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1016/j.fct.2025.115774\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"FOOD SCIENCE & TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Food and Chemical Toxicology","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1016/j.fct.2025.115774","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"FOOD SCIENCE & TECHNOLOGY","Score":null,"Total":0}
RIFM Natural Complex Substance (NCS) fragrance ingredient safety assessment, benzoin infusion, Sumatra, CAS Registry Number 9000-05-9, RIFM ID 104-K2.31.
Benzoin infusion, Sumatra was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, photoirritation/photoallergenicity, skin sensitization, and environmental safety. Data for the components of the NCS do not show a concern for genotoxicity. Benzoin infusion, Sumatra was evaluated for the repeated dose and reproductive toxicity endpoints on the basis of component analysis using a combination of target data, read-across data, and the threshold of toxicological concern (TTC); benzoin infusion, Sumatra is safe for use under the conditions described in this safety assessment for the repeated dose and reproductive toxicity endpoints. Data for the components of the NCS do not show a concern for skin sensitization under the current, declared levels of use. The photoirritation endpoint was evaluated based on data and ultraviolet/visible (UV/Vis) absorption spectra for the components of the NCS; benzoin infusion, Sumatra is not expected to be photoirritating. Benzoin infusion, Sumatra has not been fully evaluated for photoallergenicity due to a lack of suitable data and validated in vitro tests. To address this data gap, RIFM is sponsoring an in vitro photoallergy research program to evaluate the photoallergy potential of benzoin infusion, Sumatra. The local respiratory toxicity endpoint for this NCS was evaluated using the inhalation TTC for a Cramer Class III material, and the inhalation exposure to benzoin infusion, Sumatra is below the TTC (0.47 mg/day). Based on the component assessment, benzoin infusion, Sumatra does not contain Persistent, Bioaccumulative, and Toxic (PBT) or very Persistent, very Bioaccumulative (vPvB) components as per the IFRA Environmental Standards. In addition, following the RIFM Environmental Framework and based on individual component assessment, benzoin infusion, Sumatra does not present a risk to the aquatic environment (i.e., its screening-level PEC/PNEC <1) at the current reported VoU.
期刊介绍:
Food and Chemical Toxicology (FCT), an internationally renowned journal, that publishes original research articles and reviews on toxic effects, in animals and humans, of natural or synthetic chemicals occurring in the human environment with particular emphasis on food, drugs, and chemicals, including agricultural and industrial safety, and consumer product safety. Areas such as safety evaluation of novel foods and ingredients, biotechnologically-derived products, and nanomaterials are included in the scope of the journal. FCT also encourages submission of papers on inter-relationships between nutrition and toxicology and on in vitro techniques, particularly those fostering the 3 Rs.
The principal aim of the journal is to publish high impact, scholarly work and to serve as a multidisciplinary forum for research in toxicology. Papers submitted will be judged on the basis of scientific originality and contribution to the field, quality and subject matter. Studies should address at least one of the following:
-Adverse physiological/biochemical, or pathological changes induced by specific defined substances
-New techniques for assessing potential toxicity, including molecular biology
-Mechanisms underlying toxic phenomena
-Toxicological examinations of specific chemicals or consumer products, both those showing adverse effects and those demonstrating safety, that meet current standards of scientific acceptability.
Authors must clearly and briefly identify what novel toxic effect (s) or toxic mechanism (s) of the chemical are being reported and what their significance is in the abstract. Furthermore, sufficient doses should be included in order to provide information on NOAEL/LOAEL values.